- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03352323
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
November 5, 2021 updated by: Padagis LLC
Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea
the study will measure the decrease in redness on the face of rosacea subjects
Study Overview
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
College Station, Texas, United States, 77845
- J&S Studies
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non-pregnant, non-lactating female, 18 years of age or older.
- Signed informed consent form that meets all criteria of current Food and Drug Administration regulations.
- Females of childbearing potential must not be pregnant or lactating.
- Females of childbearing potential must agree to the use of a reliable method of contraception throughout the study.
- Have clinical diagnosis of rosacea with persistent (non-transient) facial erythema.
- Have < 3 inflammatory lesions on the face.
- Have an erythema score of 3 (moderate) or 4 (severe) for both the CEA and the PSA that is reflective of the overall targeted areas.
- Willing to minimize external factors that might trigger rosacea flare-ups (e.g., spicy foods, hot drinks, hot environments, prolonged sun exposure, strong winds, emotional stress and alcoholic beverages) during the study.
Exclusion Criteria:
- Forms of rosacea that, in the opinion of the Investigator, would interfere with the diagnosis or assessment of study endpoints
- Patient has a skin condition that, in the opinion of the Investigator, would interfere with the diagnosis or assessment of rosacea
- Patients with active sunburn or excessive facial hair such as beards, sideburns, moustaches, etc.
- Patients with moderate to severe telangiectasial masses
- History of blood dyscrasia.
- Significant history or current evidence of any uncontrolled chronic or serious disease or medical condition that would, in the judgment of the Investigator, would put the subject at undue risk or compromise the study assessments.
- History or current evidence of Raynaud's syndrome, severe, unstable or uncontrolled cardiovascular disease, orthostatic hypotension, uncontrolled hypertension or hypotension, thromboangiitis obliterans, cerebral or coronary insufficiency, renal or hepatic or renal impairment, scleroderma, Sjögren's syndrome, depression, or narrow-angle glaucoma to an extent that, in the opinion of the Investigator, would place the subject at undue risk.
- Female patients taking hormonal contraceptives or oral estrogen for less than one month or those that plan to change the dosage regimen during the course of the study.
- Previous participation in this study.
- Employees of the Investigator or research center or their immediate family members.
- Inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: oxymetazoline cream
|
RLD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Responder
Time Frame: Day 15
|
Responder is defined as a 2-grade improvement from pre-dose on Day 1 on both the Clinician Erythema Assessment and Patient Self Assessment scales
|
Day 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 18, 2017
Primary Completion (Actual)
December 6, 2017
Study Completion (Actual)
March 30, 2018
Study Registration Dates
First Submitted
November 7, 2017
First Submitted That Met QC Criteria
November 21, 2017
First Posted (Actual)
November 24, 2017
Study Record Updates
Last Update Posted (Actual)
November 8, 2021
Last Update Submitted That Met QC Criteria
November 5, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Manifestations
- Rosacea
- Erythema
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Respiratory System Agents
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Phenylephrine
- Oxymetazoline
Other Study ID Numbers
- PRG-NY-17-013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erythema
-
Tufts Medical CenterRecruiting
-
VIST - Faculty of Applied SciencesRecruitingMinimal Erythema DoseSlovenia
-
University of British ColumbiaUnknownSurgical Scar ErythemaCanada
-
VIST - Faculty of Applied SciencesEuropean Regional Development Fund; Slovenian Research Agency; Valens Int. d.o... and other collaboratorsCompletedDermis Density | Minimal Erythema Dose | Skin ViscoelasticitySlovenia
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingErythema Multiforme
-
Robert MichelettiRecruiting
-
Skin Laser & Surgery SpecialistsGalderma R&DTerminatedErythema and Flushing Associated With Rosacea
-
National Institute of Allergy and Infectious Diseases...Completed
-
University Medical Centre LjubljanaUnknown
-
Postgraduate Institute of Medical Education and...CompletedErythema Nodosum LeprosumIndia
Clinical Trials on Oxymetazoline
-
Guangzhou Women and Children's Medical CenterCompletedAdenoidal Hypertrophy
-
Taro Pharmaceuticals USACompleted
-
Actavis Inc.Teva Pharmaceuticals USACompletedRosaceaUnited States
-
AllerganCompletedErythema | RosaceaUnited States
-
University of ChicagoGlaxoSmithKlineCompleted
-
RDD Pharma LtdCompletedFecal Incontinence | Spinal Cord InjuryHungary
-
University of South FloridaTerminated
-
Mahidol UniversityCompletedNasal Obstruction Present FindingThailand
-
Federal University of Rio Grande do SulHospital de Clinicas de Porto Alegre; Coordenação de Aperfeiçoamento de Pessoal... and other collaboratorsCompletedPolycystic Ovary Syndrome
-
AllerganCompletedErythema | RosaceaUnited States